Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study
暂无分享,去创建一个
Johan F. Langenhuijsen | Egbert Oosterwijk | Otto C. Boerman | Mark Rijpkema | W. Oyen | J. Langenhuijsen | P. Mulders | E. Oosterwijk | O. Boerman | M. Hekman | M. Rijpkema | Wim J. Oyen | Christina A. Hulsbergen-Van de Kaa | Marlène C. Hekman | Constantijn H. Muselaers | Peter F. Mulders | C. Hulsbergen–van de Kaa | Constantijn H. J. Muselaers
[1] P. Low,et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results , 2011, Nature Medicine.
[2] Klaus Jeschke,et al. Positive surgical margins after nephron-sparing surgery. , 2012, European urology.
[3] W. Oyen,et al. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] W. Oyen,et al. Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors. , 2015, Molecular imaging.
[5] W. Oyen,et al. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. , 2013, European urology.
[6] P. Low,et al. Novel Use of Folate-Targeted Intraoperative Fluorescence, OTL38, in Robot-Assisted Laparoscopic Partial Nephrectomy: Report of the First Three Cases , 2016, Journal of endourology case reports.
[7] Edward Messing,et al. Near infrared fluorescence imaging after intravenous indocyanine green: initial clinical experience with open partial nephrectomy for renal cortical tumors. , 2012, Urology.
[8] K. Bensalah,et al. Partial Nephrectomy for Large or Complex Masses: Option or Obsolete? , 2017, European Urology.
[9] F. Debruyne,et al. Immunohistochemical analysis of intratumoral heterogeneity of [131I]cG250 antibody uptake in primary renal cell carcinomas. , 1998, British Journal of Cancer.
[10] J. Ferlay,et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.
[11] J. Humm,et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. , 2007, The Lancet. Oncology.
[12] J. A. van der Laak,et al. Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC , 2015, Neoplasia.
[13] Shuming Nie,et al. Intraoperative molecular imaging can identify lung adenocarcinomas during pulmonary resection. , 2015, The Journal of thoracic and cardiovascular surgery.
[14] P. Low,et al. Intraoperative Molecular Diagnostic Imaging Can Identify Renal Cell Carcinoma. , 2016, The Journal of urology.
[15] W. Oyen,et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] W. Oyen,et al. Radionuclide and Fluorescence Imaging of Clear Cell Renal Cell Carcinoma Using Dual Labeled Anti-Carbonic Anhydrase IX Antibody G250. , 2015, The Journal of urology.
[17] F. Debruyne,et al. Tumor retention of 186Re-MAG3, 111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts. , 1998, Cancer biotherapy & radiopharmaceuticals.
[18] C. Meyer,et al. The Adoption of Nephron-Sparing Surgery in Europe - A Trend Analysis in Two Referral Centers from Austria and Germany , 2015, Urologia Internationalis.
[19] J. Frangioni. In vivo near-infrared fluorescence imaging. , 2003, Current opinion in chemical biology.
[20] W. Oyen,et al. Optical Imaging of Renal Cell Carcinoma with Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab , 2014, The Journal of Nuclear Medicine.
[21] Vasilis Ntziachristos,et al. Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study , 2016, Clinical Cancer Research.
[22] Joshua S Richman,et al. Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer , 2015, Clinical Cancer Research.
[23] P. Choyke,et al. PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study , 2015, Abdominal Radiology.
[24] P. Mulders,et al. Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model , 2017, The Journal of Nuclear Medicine.
[25] R. Autorino,et al. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. , 2017, European urology.
[26] Steven P. Larson,et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] F. Debruyne,et al. Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. , 1999, Anticancer research.
[28] P. Bunn,et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.
[29] P. Mulders,et al. Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study , 2016, Clinical Cancer Research.
[30] Hiroaki Shiina,et al. Indocyanine green (ICG)-based fluorescence navigation system for discrimination of kidney cancer from normal parenchyma: application during partial nephrectomy , 2012, International Urology and Nephrology.
[31] S. Larson,et al. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[32] W. Oyen,et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. , 2013, European urology.
[33] A. L. Vahrmeijer,et al. Characterization and Evaluation of the Artemis Camera for Fluorescence-Guided Cancer Surgery , 2014, Molecular Imaging and Biology.
[34] W. Oyen,et al. Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging , 2012, The Journal of Nuclear Medicine.
[35] Edward Messing,et al. Robot-assisted and laparoscopic partial nephrectomy with near infrared fluorescence imaging. , 2012, Journal of endourology.
[36] Christopher H Contag,et al. Regulatory Aspects of Optical Methods and Exogenous Targets for Cancer Detection. , 2017, Cancer research.
[37] S. Herrell,et al. Second prize: frequency of benign renal cortical tumors and histologic subtypes based on size in a contemporary series: what to tell our patients. , 2007, Journal of endourology.
[38] R. Autorino,et al. Outcomes of Laparoscopic and Robotic Partial Nephrectomy for Large (>4 Cm) Kidney Tumors: Systematic Review and Meta-Analysis , 2017, Annals of Surgical Oncology.
[39] Vasilis Ntziachristos,et al. Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer. , 2016, Cancer research.
[40] Melissa L. Korb,et al. IND-Directed Safety and Biodistribution Study of Intravenously Injected Cetuximab-IRDye800 in Cynomolgus Macaques , 2015, Molecular Imaging and Biology.